Get the Stockscreener App
39.85
5.99%
-2.54
Akero Therapeutics Inc stock is traded at $39.85, with a volume of 1.33M.
It is down -5.99% in the last 24 hours and up +6.66% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$42.39
Open:
$42.39
24h Volume:
1.33M
Relative Volume:
1.25
Market Cap:
$3.58B
Revenue:
-
Net Income/Loss:
$-237.22M
P/E Ratio:
-10.54
EPS:
-3.78
Net Cash Flow:
$-212.64M
1W Performance:
-11.19%
1M Performance:
+6.66%
6M Performance:
+15.67%
1Y Performance:
+91.59%
1-Day Range:
$39.66
$44.81
1-Week Range:
$39.66
$45.24
52-Week Range:
$17.86
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
39.85 | 3.58B | 0 | -237.22M | -212.64M | -3.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der Fibrose ohne Verschlechterung der MASH - GlobeNewswire Inc.
Akero Therapeutics Reveals AI-Based Analysis Supporting Efruxifermin's Antifibrotic Activity in Phase 2b HARMONY Trial for Pre-Cirrhotic MASH - Nasdaq
Akero Therapeutics and HistoIndex Present New Analyses of - GlobeNewswire
Akero Therapeutics, Inc. and HistoIndex Present New Analyses of Phase 2b Harmony Trial in Oral and Poster Presentations at the EASL Congress 2025 - marketscreener.com
Long Term Trading Analysis for (AKRO) - news.stocktradersdaily.com
Dimensional Fund Advisors LP Boosts Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Balyasny Asset Management L.P. Invests $18.06 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Trading Down 6% After Insider Selling - Defense World
Renaissance Technologies LLC Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
8,390 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Susquehanna Fundamental Investments LLC - MarketBeat
Akero Therapeutics Reports Positive Trial Data for Prospective Cirrhosis Drug - marketscreener.com
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine - GlobeNewswire
Deep Track Capital LP Purchases 800,216 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero reports promising cirrhosis treatment trial results - Investing.com
Akero Therapeutics Presents Week 96 Results from Phase 2b - GlobeNewswire
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 - Yahoo Finance
Akero Therapeutics Presents Phase 2b SYMMETRY Trial Results Significant for Efruxifermin in Treating Fibrosis in Compensated Cirrhosis Due to MASH at EASL Congress 2025 - Nasdaq
Alkeon Capital Management LLC Trims Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation - ACCESS Newswire
Cutter Capital Management LP Invests $6.40 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Aquatic Capital Management LLC Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Schonfeld Strategic Advisors LLC Sells 16,028 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
5AM Venture Management LLC Invests $4.59 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics to Present at BofA Securities 2025 Health Care Conference - Nasdaq
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference - Stock Titan
Akero Therapeutics Inc expected to post a loss of 97 cents a shareEarnings Preview - TradingView
No Stopping Akero Therapeutics Inc (NASDAQ: AKRO)’s Stock Plunged? - Stocksregister
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Holdings Decreased by Envestnet Asset Management Inc. - Defense World
Akero Therapeutics (AKRO) to Release Earnings on Friday - MarketBeat
Tower Research Capital LLC TRC Has $450,000 Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Pharma Co. Escapes Investor Liver Drug Trial Suit, For Now - Law360
Akero Beats Investor Suit Over Liver Drug Trial Design for Now - Bloomberg Law News
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $76.29 Consensus Target Price from Brokerages - MarketBeat
Long-Term Shareholders Have Rights – If You Hold Akero - GlobeNewswire
Long-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); ... - Bluefield Daily Telegraph
Long-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Mercury Systems, Inc. (NASDAQ: MRCY); or Virtu Financial Inc. (NASDAQ: VIRT), Contact Grabar La - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Renaissance Technologies LLC Invests $579,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Emerald Mutual Fund Advisers Trust Trims Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Invesco Ltd. Purchases 21,086 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
T. Rowe Price Investment Management Inc. Decreases Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Foresite Capital Management VI LLC Makes New $10.15 Million Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $256,437.50 in Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Price T Rowe Associates Inc. MD - MarketBeat
Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Target Price at $76.29 - Defense World
Akero Therapeutics (AKRO) Projected to Post Quarterly Earnings on Friday - Defense World
Dark Forest Capital Management LP Buys Shares of 16,893 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Wells Fargo & Company MN Acquires 7,587 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
How does Akero Therapeutics Inc (AKRO) change from a tortoise to a hare? - Sete News
AKRO’s 2023 Market Dance: Up 63.95% – Time to Invest? - investchronicle.com
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):